Literature DB >> 23460403

Upper airway inflammation exacerbates bronchial hyperreactivity in mouse models of rhinosinusitis and allergic asthma.

Kai-Li Liang1, Rong-San Jiang, Ren-Ching Wang, Malcolm Koo, Shyh-Chang Chen, Wan-Chun Huang, Yueh-Chiao Yeh.   

Abstract

BACKGROUND: Recent studies have suggested that upper airway inflammation has a strong impact on lower airway diseases. The purpose of this study was to assess whether nasal inflammation could exacerbate allergic asthma in a mouse model.
METHODS: Mice were assigned to 4 groups: control (Cont), either rhinosinusitis (R) or allergic asthma (A) alone, and both rhinosinusitis and allergic asthma (R&A). Mice underwent induction of nasal inflammation (R and R&A) or sham surgery (Cont and A) on day 1. Mice in the A and R&A groups were sensitized to ovalbumin on days 1, 7, and 14, followed by aerosol challenge on days 18 to 20, whereas in the Cont and R groups only saline was administered. All mice were assessed for airway hyperresponsiveness (AHR) and were euthanized on day 21. The sera, bronchoalveolar lavage fluids (BALFs), and nasal and lung tissues were collected for further analyses.
RESULTS: Histology findings confirmed upper and lower airway inflammation in experimental mice. Significantly increased AHR and total serum immunoglobulin E (IgE) were observed in the R&A group when compared with those of the Cont, R, and A groups. Responses to IgG2a induction were also found in sera and BALFs from mice with rhinosinusitis (R and R&A). Higher levels of interleukin 4 (IL-4) and IL-13, and increased eosinophilic inflammation were detected in BALFs and lung tissues from the experimental groups when compared with those from the Cont group.
CONCLUSION: Our results confirm that upper airway inflammation could exacerbate allergic asthma, and provide support to the concept of "one airway, one disease.
© 2013 ARS-AAOA, LLC.

Entities:  

Keywords:  allergen; allergic rhinitis; asthma; bronchial hyperreactivity; mouse; ovalbumin; rhinosinusitis

Mesh:

Substances:

Year:  2013        PMID: 23460403     DOI: 10.1002/alr.21160

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  2 in total

1.  Erythromycin reduces nasal inflammation by inhibiting immunoglobulin production, attenuating mucus secretion, and modulating cytokine expression.

Authors:  Ting-Ting Yen; Rong-San Jiang; Ching-Yun Chang; Chih-Ying Wu; Kai-Li Liang
Journal:  Sci Rep       Date:  2021-11-05       Impact factor: 4.379

2.  Anti-Inflammatory Effects of a Cordyceps sinensis Mycelium Culture Extract (Cs-4) on Rodent Models of Allergic Rhinitis and Asthma.

Authors:  Jihang Chen; Wing Man Chan; Hoi Yan Leung; Pou Kuan Leong; Choly Tat Ming Yan; Kam Ming Ko
Journal:  Molecules       Date:  2020-09-04       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.